0000008063-26-000025
SEC filingStrong revenue growth driven by Aerospace segment, with margin expansion from higher volume and operational efficiencies, resulting in net income more than doubling.
Consolidated revenue for Q1 2026 was $230.6 million, up 12.0% from $205.9 million in Q1 2025, driven primarily by the Aerospace segment's strong demand in Commercial Transport and General Aviation. Gross profit increased 23.5% to $75.1 million, with gross margin expanding 310 basis points to 32.6%, reflecting volume leverage and improved production efficiencies. SG&A decreased 2.3% to $35.8 million, aided by a $1.2 million decline in litigation-related expenses and the absence of a $6.2 million reserve adjustment related to the UK patent dispute in the prior year, partially offset by higher wages and incentive compensation. Research and development expenses rose $1.0 million to $12.1 million due to project timing. Net interest expense declined 25.8% to $2.3 million following the September 2025 refinancing. The effective tax rate was (3.0)% compared to 6.3% in the prior year, benefiting from a $2.7 million discrete adjustment for expected stock-based compensation deductions and a valuation allowance reversal. Net income more than doubled to $25.5 million ($0.67 per diluted share) from $9.5 million ($0.26 per diluted share).
Aerospace: Segment sales grew 11.7% to $213.8 million, with Commercial Transport up 13.7% to $156.4 million driven by seat motion and lighting & safety products. General Aviation surged 40.7% to $21.4 million on higher IFEC product sales to the VVIP market. Military Aircraft sales were flat at $33.5 million, while Other sales declined $2.9 million due to wind-down of non-core contract manufacturing. Operating profit improved 58.7% to $35.3 million, with operating margin expanding to 16.5% from 11.6%, supported by volume leverage, a $2.8 million catch-up profit on the MV-75 program, and a $7.0 million reduction in litigation costs. Bookings were $264.4 million (book-to-bill 1.24:1), and backlog ended at $651.4 million.
Test Systems: Sales increased 15.4% to $16.8 million, as the prior year was negatively impacted by a $1.9 million cost revision on a mass transit contract. Operating profit turned positive at $0.4 million (2.4% margin) versus a loss of $2.2 million in Q1 2025, but profitability remains constrained by mix and under-absorption of fixed costs. Bookings were $26.1 million (book-to-bill 1.55:1), with backlog of $83.0 million.
Management expects cash flow from operations to fund capital expenditures and obligations, though no specific numerical guidance is provided. The company is monitoring production ramp-ups at Boeing and Airbus and aligning operations accordingly. The impact of tariffs (approximately $2.5 million in Q1) and trade policy remains uncertain, with potential material effects. Key challenges include supply chain pressures, labor availability, and the ability to pass through cost increases. The company continues to pursue growth through acquisitions (Envoy Aerospace and BMA in 2025) and organic initiatives. Compliance with financial covenants under the new $300 million Revolving Credit Facility is maintained as of April 4, 2026.
Cash and cash equivalents stood at $11.9M, down from $18.2M at year-end 2025, primarily due to $11.2M in capital expenditures and $5.4M in stock award activity. Total debt was $334.9M, consisting of $85.0M drawn on the revolving credit facility and $249.9M carrying value of convertible notes (including $32.0M of 2030 Notes and $217.8M of 2031 Notes). The company maintains $212.8M of additional borrowing capacity under the revolver. Shareholders' equity increased to $161.7M from $140.1M, driven by net income of $25.5M.
Total remaining performance obligations (backlog) were $734.3M as of April 4, 2026, with $596.2M expected to be recognized as revenue within the next twelve months. The company also has capitalized fulfillment costs of $6.3M. There are no significant purchase commitments explicitly disclosed beyond normal procurement.
No share repurchases were executed during the quarter; $41.5M remains authorized for buybacks. The ATM program has $8.2M remaining capacity. Capital expenditures totaled $11.2M (4.8% of sales), with $10.7M in Aerospace and $0.4M in Test Systems. Debt activity: the $225.0M 2031 Convertible Notes were issued in September 2025, and $132.0M of the 2030 Notes were repurchased. Net debt increased marginally by $0.4M from year-end 2025.
Aerospace segment sales were $213.8M (92.7% of total), up 11.7% YoY, driven by strong growth in Commercial Transport ($156.4M) and Seat Motion ($19.9M, up from $6.7M). Operating margin improved to 16.5% from 11.6%. Test Systems sales were $16.8M (up 15.4%), swinging from an operating loss of $(2.2M) to a profit of $0.4M, margin 2.4%. No further geographic mix detail was provided in the notes.
Operating cash flow (CFO) of $10.6M was significantly lower than net income of $25.5M, indicating poor cash conversion. The primary drivers were large working capital outflows: accounts receivable increased by $13.4M, inventories by $16.4M, and accrued expenses decreased by $6.7M. These were partially offset by a $15.0M increase in accounts payable and a $3.6M rise in customer advances. Non-cash adjustments (depreciation, stock compensation, etc.) totaled $12.7M. The operating cash flow decline from $20.6M in the prior year reflects these working capital swings.
Capital expenditures surged to $11.2M, more than five times the prior year's $2.1M, signaling heavy investment. As a result, free cash flow (CFO minus capex) was negative $0.6M, compared to positive $18.5M a year ago. The company did not report any share repurchases or dividends; the $5.4M financing outflow for stock award activity relates to tax withholding for equity grants.
Overall, cash generation weakened substantially due to working capital build and increased capex. The negative free cash flow and reliance on debt (proceeds of $30M offset by $30M repayments) suggest careful monitoring of liquidity.